Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Talecris_Biotherapeutics
Baxter International's Bio Science division ZLB Behring |
| gptkbp:employees |
Over 25,000
|
| gptkbp:focus_area |
gptkb:healthcare_organization
gptkb:Cardiovascular_diseases gptkb:vaccine gptkb:Public_health Cell therapy Gene therapy Genetic disorders Regenerative medicine Transplantation Autoimmune diseases Clinical trials Hemophilia Neurology Infectious diseases Personalized medicine Patient care Vaccines Metabolic disorders Chronic diseases Global health initiatives Critical care Healthcare solutions Alpha-1 antitrypsin deficiency Blood transfusion medicine Primary immunodeficiency Rare blood disorders |
| gptkbp:founded |
1904
|
| gptkbp:global_presence |
More than 60 countries
|
| gptkbp:headquarters |
gptkb:King_of_Prussia,_Pennsylvania,_USA
|
| https://www.w3.org/2000/01/rdf-schema#label |
CSL Behring Gmb H
|
| gptkbp:industry |
gptkb:Company
|
| gptkbp:key_people |
gptkb:S._Scott_Mc_Culloch
gptkb:Paul_Perreault gptkb:J._Michael_Mc_Ginnis Christine Carr Graham M. Melrose |
| gptkbp:operates_in |
Biopharmaceuticals
|
| gptkbp:parent_company |
gptkb:CSL_Limited
|
| gptkbp:part_of |
CSL Group
|
| gptkbp:products |
Immunoglobulin
Coagulation factor |
| gptkbp:research_focus |
Rare diseases
|
| gptkbp:subsidiary |
gptkb:CSL_Limited
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:website |
www.cslbehring.com
|
| gptkbp:bfsParent |
gptkb:CSL_Behring
|
| gptkbp:bfsLayer |
7
|